84 results about "Exogenous antigen" patented technology

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. Optionally, the methods further comprise administering antigen presenting cells sensitized with complexes of hsps noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. In a specific embodiment, the effective amounts of the complex are in the range of 0.1 to 9.0 micrograms for complexes comprising hsp70, 5 to 49 micrograms for hsp90, and 0.1 to 9.0 micrograms for gp96.

Methods for eliciting in an animal in need thereof a cell-mediated immune response specific to an antigen, the method comprising providing an antigen preparation comprising particles on the surface of which the antigen is attached, and administering the antigen preparation to the animal, wherein the particles are taken up by antigen presenting cells (APC) of the animal via phagocytosis, forming a phagosome inside the APC, wherein the antigen is attached to the surface of the particle in such a way that the antigen is released in the phagosome before the phagosome fuses with a late endosome or a lysosome, and wherein the antigen is cross-presented on a Class I MHC molecule. Also provided are particulate antigen preparations or particulate vaccines that can be delivered to an animal in need thereof for vaccination against, for preventing or treating, a disease related to the antigen, such as cancer and a viral infection.

The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases. The methods of the invention comprise administering a composition comprising an effective amount of a complex, in which the complex consists essentially of a heat shock protein (hsp) noncovalently bound to an antigenic molecule. "Antigenic molecule" as used herein refers to the peptides with which the hsps are endogenously associated in vivo as well as exogenous antigens/immunogens (i.e., with which the hsps are not complexed in vivo) or antigenic/immunogenic fragments and derivatives thereof. In a preferred embodiment, the complex is autologous to the individual. The effective amounts of the complex are in the range of 10-600 micrograms for complexes comprising hsp70, 50-1000 micrograms for hsp90, and 10-600 micrograms for gp96. The invention also provides a method for measuring tumor rejection in vivo in an individual, preferably a human, comprising measuring the generation by the individual of MHC Class I-restricted CD8+ cytotoxic T lymphocytes specific to the tumor. Methods of purifying hsp70-peptide complexes are also provided.

The present invention encompasses a recombinant bacterium comprising a regulated rfaH nucleic acid, as well as a vaccine comprising said recombinant bacterium. Other embodiments of the present invention encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and a regulated rfc nucleic acid, while additional embodiments encompass a recombinant bacterium comprising a regulated rfaH nucleic acid and at least one nucleic acid encoding at least one exogenous antigen.

Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.

A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naïve T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T-cells and exposing the naïve T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.

A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α₁.

Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic cancer are disclosed. In one embodiment, human dendritic cells exposed to a tumor associated antigen, or an antigenic fragment thereof in combination with bacillus Calmette-Guerin (BCG), are administered to a cancer patient to activate a predominantly CD8⁺T cell response in vivo. In an alternate embodiment, human dendritic cells are exposed to a tumor associated antigen or a specific antigenic peptide in combination with BCG in vitro and incubated or cultured with primed or unprimed T cells to activate a predominantly CD8⁺T cell response in vitro. The activated T cells are then administered to a cancer patient. Antigen in combination with BCG is processed by dendritic cells through the MHC-CLASS I compartment which provides for a predominantly CD8⁺T cell response. The addition of LPS provides for a greater number of mature dendritic cells enhancing the T cell response to antigen. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.

The invention provides a construction method for delaying attenuation and increasing an expression exogenous antigen salmonella suipestifer carrier through regulation and control of gene, which is characterized in that receptor bacterium C78-3 is combined with manA, crp, relA and asd -containing deleted suicide carrier escherichia coli donor bacterium, mutants delta manA, delta Pcrp: : TT ara C PBAD crp, delta relA: : araC PBAD lacI TT and delta asd A are introduced in wild-type salmonella suipestifer C78-3, the introduced salmonella suipestifer after mutation can be called x0011; and four types of mutation enable phenotype identification. The method of the invention makes salmonella suipestifer to become safe and effective vaccine carrier of many exogenous antigens; and provides the delaying attenuation and increasing expression exogenous antigen salmonella suipestifer carrier through regulation and control of gene for various pig diseases, especially many bacteria diseases of pig, and has great market applicability.

The invention provides an attenuated vector bacterium of salmonella choleraesuls and a construction method of the attenuated vector bacterium and belongs to the technical field of animal bacterium genetic engineering. The attenuated vector bacterium is C78-3 salmonella choleraesuls without deltamanA, deltacrp::TT araC PBAD, deltarelA:: araC PBAD lacI TT, deltasoB and deltaasdA genes and is named as rSC0016. The method for taking a suicide vector without a resistance marker as a salmonella choleraesuls constructing vector is adopted and the utilization of the vector marked with antibiotics can be avoided; the vector can be safely used in clinical practice; furthermore, a balanced lethal system carries an exogenous antigen and can guarantee that only vaccine strains carrying the exogenous antigen can be used for producing vaccines and enter a host and survive, so that the immunity efficiency of the vaccines is improved.

Whole-cell vaccines and methods for enhancing the immunogenicity of cellular microorganisms for use in producing protective immune responses in vertebrate hosts subsequently exposed to pathogenic bacteria or for use as vectors to express exogenous antigens and induce responses against other infectious agents or cancer cells. The present invention involves an additional method of enhancing antigen presentation by intracellular bacteria in a manner that improves vaccine efficacy. After identifying an enzyme that has an anti-apoptotic effect upon host cells infected by an intracellular microbe, the activity of the enzyme produced by the intracellular microbe is reduced by expressing a mutant copy of the enzyme, thereby modifying the microbe so that it increases immunogenicity.

The invention belongs to the technical field of biology and specifically relates to an antigenic epitope displaying method based on a single domain antibody. Specifically, an exogenous antigenic epitope is displayed in a CDR3 region of the single domain antibody, and the single domain antibody skeleton protein which displays the exogenous antigenic epitope on the surface of a molecule can be used for preparing an antibody with a too small epitope, be also used as a substitutive antigen of an exogenous antigen and used for immunizing animals and preparing antibodies aiming at the exogenous antigen. In addition, the antigenic epitope displaying method based on a single domain antibody skeleton can also be used for preparing epitope vaccins.

Uracil auxotroph mutants of apicomplexans are provided which lack a functional carbamoyl phosphate synthase II (CPSII) enzyme. Also provided are T. gondii autoxtroph mutants which express exogenous antigens, and methods of protecting an animal against a T. gondii and non-T. gondii disease.

The invention provides a recombined sheep poxvirus transfer vector. A vector containing resistance genes and a plasmid replicon sequence and adopting Hind III and Avr II for digestion, such as a pVAX1 vector, is adopted, a DNA segment is inserted via introducing Hind III and Avr II enzyme cutting sites; the DNA segment comprises a gene sequence of a homologous arm with bidirectional poxvirus promoters and a sheep poxvirus TK gene. The invention further provides a recombined sheep poxvirus containing the recombined sheep poxvirus transfer vector and application of the recombined sheep poxvirus in the transfer of an exogenous antigen. Exogenous genes can be conveniently inserted into the recombined sheep poxvirus transfer vector, provided by the invention; moreover, the recombined sheep poxvirus transfer vector is improved according to a recombination result, and finally higher recombination efficiency is realized, accordingly, a good basis for the research and preparation of such recombination vaccines is laid.

The invention, which belongs to the field of biological medicines, in particular, relates to an improved therapeutic T cell and a method of making the same. Specifically, according to the invention, co-expression of exogenous antigen-specific receptor protein (for example, TCR or CAR) and a dominant negative TGF-beta type II receptors in a T cell is realized by means of ransduction by a lentiviralvector and thus an improved therapeutic T cell ( a TCR-T or CAR-T cell) is prepared.

The invention relates to a Salmonella choleraesuis double-gene-deletion strain free of a resistance marker, Salmonella choleraesuis C7822 (with an accession number of CCTCC NO: M2011402 ). The strain is obtained by carrying out deletion of the asd gene, one of the important nutrition and metabolism genes of Salmonella choleraesuis, on Salmonella choleraesuis C7821 (with an accession number of CCTCC NO: M2010102 ) which has undergone deletion of the crp virulence gene. The gene-deletion strain C7822 loses the capability of synthesizing diaminopimelic acid (DAP), so the strain cannot survive in a DAP negative environment. After plasmids containing the asd gene are transformed into C7822, the asd gene in the plasmids can form a complementary gene with C7822, which enables C7822 to regain the capability of surviving in a DAP negative environment. The double-gene-deletion strain C7822 obtained in the invention has distinct genetic background, strong security and no resistance marker and can stably carry and express exogenous antigens; the double-gene-deletion strain is a good carrying vector and expression strain for exogenous antigens and has a wide application prospect.

The present invention relates to Equine Herpes Virus (EHV) vectors comprising at least one exogenous antigen encoding sequence relating to a pathogen infecting food producing animals, wherein said exogenous antigen encoding sequence is inserted into an insertion site, preferably ORF70, and said exogenous antigen encoding sequence is operably linked to a promoter sequence, preferably the promoter sequence comprising 4pgG600 (SEQ ID NO:1) or 4pMCP600 (SEQ ID NO:2) or the complementary nucleotide sequences thereof or a functional fragment or a functional derivative thereof or the complementary nucleotide sequences thereof. Furthermore, the present invention relates to methods for immunizing a food producing animal comprising administering to such food producing animal an immunogenic composition comprising embodiments of the present invention. Moreover, the present invention relates to methods for the treatment or prophylaxis of clinical signs caused by swine influenza virus in a food producing animal.